Status:
UNKNOWN
Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients
Lead Sponsor:
Sohaib Ashraf
Conditions:
Coronavirus Infection
COVID
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
PHASE2
Brief Summary
To measure the effect of Ivermectin (sub-cutaneous) with or without zinc in treating the COVID-19 patients to clear viral load of SARS-CoV-2 along with reduction in severity of symptoms and length of ...
Detailed Description
This is a parallel assigned, randomized, controlled, multi-armed, investigator Initiated interventional study is designed to demonstrate efficacy to lower the viral load of COVID-19 and to demonstrate...
Eligibility Criteria
Inclusion
- Nasopharyngeal RT-PCR positive SARS-CoV-2 patient with mild to moderate disease
- Age 18 and above
- BMI 18-28 kg/m
Exclusion
- Allergy to any drug
- Co-morbidities: any pre-existing cardiac disease, pulmonary disease
- Arrhythmias
- Pregnancy
- RT-PCR performed \>3 days prior to enrollment
Key Trial Info
Start Date :
November 14 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2021
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04472585
Start Date
November 14 2020
End Date
October 30 2021
Last Update
February 17 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Ali Clinic
Lahore, MA, Pakistan, 54600
2
Shaikh Zayed Hospital
Lahore, Punjab Province, Pakistan, 54600